Webinar

Spatial Biomarker Panels for Clinical Trials

Available on-demand

60 Minutes

Most immuno-oncology drugs work by altering the tumor microenvironment to recruit and activate immune cells. To understand how these drugs work and how patients respond, researchers need the spatial context of several biomarkers—typically 8 to 18—to see how cells interact within the tumor. Traditional multiplex immunofluorescence (mIF) methods can’t capture this complexity at scale.

Through a case study and technology walk-through, this webinar highlights the barriers that have been broken in mIF that now enable flexible development of high performance high-plex biomarker panels, and application of those panels at the scale necessary for deriving valuable quantitative spatial insights from large cohort clinical trials.

More specifically, webinar attendees will learn:

How recent advances in mIF address previous hurdles, including: lack of validated reagents; limited ability to add custom biomarkers; high cost and low throughput associated with detecting more markers in large volume clinical trials
How incorporation of immune response biomarkers with target biomarkers provides more comprehensive insights
How CRO experts are working with pharma and using multiplex immunofluorescence to profile high-plex biomarker panels in clinical trial settings

About RareCyte: RareCyte provides innovative Precision Biology™ products and services for discovery, translational, and clinical research applications. The Orion™ spatial biology platform enables whole-slide highly multiplexed tissue analysis at clinical trial scale.

Speakers

Jennifer Bordeaux, PhD

Associate Director, Digital Pathology Services

Navigate Biopharma Services, Inc.

Jennifer Bordeaux, Ph.D. is a strategic leader with over a decade of industry experience in digital pathology. As Associate Director of Digital Pathology Solutions at Navigate Biopharma Services, she leads a team of scientists driving the adoption of multiplexed fluorescence immunochemistry assays to support clinical trial programs. Her expertise spans assay development, image analysis, and biomarker validation, with a strong focus on operational efficiency and scientific innovation. Jennifer earned her Ph.D. in Experimental Pathology from Yale University, where her research centered on biomarker validation in breast cancer using AQUA technology. She is a published author and frequent presenter in the field of quantitative pathology.

Tad George, PhD

Senior Vice President Biology R&D

RareCyte, Inc

Tad has over 15 years of startup experience dedicated to creating scientific markets for novel instrumentation platforms that span basic research, drug discovery and clinical applications. Prior to joining RareCyte, Tad has held similar positions at Biodesy, Inc. and DVS Sciences, and was Director of Biology at Amnis Corporation. Tad completed his B.A. in Biochemistry from the Univ. of Texas at Austin, Ph.D. in Immunology from UT Southwestern Medical Center at Dallas, and post-doctoral training at Immunex Corp. in Seattle.

Register here to watch on-demand!

Already registered? Click here to login.